Biohub, DOE, NIH, Google DeepMind, Meta and research partners pledge $1.8B for an open-source AI virtual cell. Read more: Explore the initiative's goals.

A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.

Matchpoint Therapeutics raised $150 million in Series B funding to advance MPT-062 toward clinical proof of concept. Explore the investors and pipeline.

SurVaxM missed its overall survival endpoint in glioblastoma, but patients 65 and younger saw a significant benefit. Read the trial results and context.

Telomir Pharmaceuticals raised $5.6 million in PIPE funding to advance Telomir-Zn toward a first-in-human TNBC trial. Read the latest funding update now.

KymaThera raised $80 million in Series B funding to advance K-1728, an oral pan-mutant selective PI3Kα inhibitor. Read what ...

Kairos Pharma’s Phase II mCRPC data show ENV-105 plus apalutamide extended median PFS to 17.7 months versus 2 months. Read ...

Zag Bio’s ZAG-101 enters a first-in-human trial for type 1 diabetes. Explore the Phase Ib/IIa LANTERN study and its planned enrollment of adults today.

EPI-321 data show increased lean muscle volume and strength after six months in six people with FSHD. Read the full Phase I/II study results and updates.

Prime Medicine has dosed the first patient in a Phase I/II trial of its H1069Q Wilson disease gene-editing therapy. Read the latest trial details today.

Vaxcyte is raising $1 billion through stock, warrants and convertible notes to advance its VAX-31 pneumococcal vaccine. Read the full offering details now.

Retension Pharmaceuticals filed an amended S-1 for a 3.3 million-share IPO to fund its RTN-001 hypertension program. See offering terms and key details.